DJ Sativa Investments PLC Total Voting Rights
RNS Number : 9279F
Sativa Investments PLC
31 October 2018
Press Release 31 October 2018
Sativa Investments PLC
("Sativa" or "the Company")
Total Voting Rights
Sativa Investments PLC (NEX: SATI), the UK's first medicinal cannabis investment vehicle, announces that the Company has 509,900,000 ordinary shares of 0.25p each in issue ("Ordinary Shares"), each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The total number of voting rights in the Company is therefore 509,900,000.
The figure of 509,900,000 Ordinary Shares should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The Directors of the Company accept responsibility for the contents of this announcement.
- Ends -
For further information please contact:
Geremy Thomas Joseph Colliver Founder & Chief Executive Officer Chief Financial Officer Sativa Investments PLC Sativa Investments PLC +44 (0) 20 7971 1255 +44 (0) 20 7971 1255 email@example.com firstname.lastname@example.org NEX Exchange Corporate Adviser Guy Miller and Lucy Williams Peterhouse Capital Limited +44 (0) 20 7469 0930 email@example.com Financial PR and IR Abchurch Communications +44 (0) 20 7469 4633 / 4634 Julian Bosdet / Dylan Mark / Alejandra Campuzano +44 (0) 20 7469 4630 Abchurch Switchboard www.abchurch-group.com SativaInvestments@abchurch-group.com
Notes to Editors
Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company's pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted. Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company's equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa acquires can either be public or private.
Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip(TM) technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.
The Company has a presence in Germany through its joint venture with Germany's Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.
Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.
The Company's Board and Medicinal Cannabis Advisory Board have a combined 60 years' industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency ("MHRA"), which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: www.sativainvestments.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.
(END) Dow Jones Newswires
October 31, 2018 12:23 ET (16:23 GMT)